vs
CareDx, Inc.（CDNA）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是CareDx, Inc.的1.6倍（$188.3M vs $117.7M），BRC Group Holdings, Inc.净利率更高（47.9% vs 2.4%，领先45.6%），CareDx, Inc.同比增速更快（39.0% vs -21.9%），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -15.4%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
CDNA vs RILY — 直观对比
营收规模更大
RILY
是对方的1.6倍
$117.7M
营收增速更快
CDNA
高出60.8%
-21.9%
净利率更高
RILY
高出45.6%
2.4%
两年增速更快
CDNA
近两年复合增速
-15.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $188.3M |
| 净利润 | $2.8M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 1.0% | 32.3% |
| 净利率 | 2.4% | 47.9% |
| 营收同比 | 39.0% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.05 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARILY
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $188.3M | ||
| Q3 25 | $100.1M | $215.3M | ||
| Q2 25 | $86.7M | $188.2M | ||
| Q1 25 | $84.7M | $197.2M | ||
| Q4 24 | $86.6M | $241.0M | ||
| Q3 24 | $82.9M | $225.5M | ||
| Q2 24 | $92.3M | $256.0M |
净利润CDNARILY
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $90.3M | ||
| Q3 25 | $1.7M | $91.1M | ||
| Q2 25 | $-8.6M | $139.5M | ||
| Q1 25 | $-10.4M | $-10.0M | ||
| Q4 24 | $87.7M | $-5.6M | ||
| Q3 24 | $-10.6M | $-284.4M | ||
| Q2 24 | $-4.6M | $-433.6M |
毛利率CDNARILY
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% |
营业利润率CDNARILY
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 32.3% | ||
| Q3 25 | -0.2% | 30.4% | ||
| Q2 25 | -12.8% | 5.7% | ||
| Q1 25 | -15.8% | -31.2% | ||
| Q4 24 | 97.5% | -69.2% | ||
| Q3 24 | -16.6% | -36.4% | ||
| Q2 24 | -7.9% | -90.8% |
净利率CDNARILY
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 47.9% | ||
| Q3 25 | 1.7% | 42.3% | ||
| Q2 25 | -9.9% | 74.1% | ||
| Q1 25 | -12.2% | -5.1% | ||
| Q4 24 | 101.3% | -2.3% | ||
| Q3 24 | -12.8% | -126.1% | ||
| Q2 24 | -5.0% | -169.4% |
每股收益（稀释后）CDNARILY
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $2.78 | ||
| Q3 25 | $0.03 | $2.91 | ||
| Q2 25 | $-0.16 | $4.50 | ||
| Q1 25 | $-0.19 | $-0.39 | ||
| Q4 24 | $1.60 | $-0.01 | ||
| Q3 24 | $-0.20 | $-9.39 | ||
| Q2 24 | $-0.09 | $-14.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | — | $-171.5M |
| 总资产 | $411.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARILY
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $226.6M | ||
| Q3 25 | $194.2M | $184.2M | ||
| Q2 25 | $186.3M | $267.4M | ||
| Q1 25 | $230.9M | $138.3M | ||
| Q4 24 | $260.7M | $146.9M | ||
| Q3 24 | $240.9M | $159.2M | ||
| Q2 24 | $228.9M | $236.9M |
总债务CDNARILY
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARILY
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $-171.5M | ||
| Q3 25 | $311.1M | $-260.5M | ||
| Q2 25 | $327.4M | $-351.7M | ||
| Q1 25 | $379.3M | $-496.8M | ||
| Q4 24 | $378.4M | $-488.2M | ||
| Q3 24 | $273.2M | $-497.6M | ||
| Q2 24 | $264.7M | $-218.3M |
总资产CDNARILY
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.7B | ||
| Q3 25 | $432.3M | $1.7B | ||
| Q2 25 | $444.3M | $1.5B | ||
| Q1 25 | $489.6M | $1.5B | ||
| Q4 24 | $491.1M | $1.8B | ||
| Q3 24 | $477.0M | $2.2B | ||
| Q2 24 | $466.8M | $3.2B |
负债/权益比CDNARILY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | — |
| 自由现金流率自由现金流/营收 | 0.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.54× | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDNARILY
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $26.2M | ||
| Q3 25 | $37.4M | $-60.6M | ||
| Q2 25 | $9.9M | $-25.6M | ||
| Q1 25 | $-26.6M | $184.0K | ||
| Q4 24 | $21.9M | $-2.7M | ||
| Q3 24 | $12.5M | $19.5M | ||
| Q2 24 | $18.9M | $111.5M |
自由现金流CDNARILY
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率CDNARILY
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金转化率CDNARILY
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | 22.30× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
